![Cells | Free Full-Text | Divergent Molecular and Cellular Responses to Low and High-Dose Ionizing Radiation Cells | Free Full-Text | Divergent Molecular and Cellular Responses to Low and High-Dose Ionizing Radiation](https://pub.mdpi-res.com/cells/cells-11-03794/article_deploy/html/images/cells-11-03794-g001.png?1669948342)
Cells | Free Full-Text | Divergent Molecular and Cellular Responses to Low and High-Dose Ionizing Radiation
![Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase | Journal of Medicinal Chemistry Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/jm201384j/asset/images/large/jm-2011-01384j_0029.jpeg)
Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase | Journal of Medicinal Chemistry
![The Fission Yeast Mating-Type Switching Motto: “One-for-Two” and “Two-for-One” | Microbiology and Molecular Biology Reviews The Fission Yeast Mating-Type Switching Motto: “One-for-Two” and “Two-for-One” | Microbiology and Molecular Biology Reviews](https://journals.asm.org/cms/asset/3ca37c6a-fe41-4dd2-9571-b14a487b10ff/mmbr.2023.87.issue-1.cover.gif)
The Fission Yeast Mating-Type Switching Motto: “One-for-Two” and “Two-for-One” | Microbiology and Molecular Biology Reviews
![Jens KIILGAARD | Professor Senior Consultant | PhD, MD, FEBO | Rigshospitalet, Copenhagen | rigshospitalet | Department of Ophthalmology | Research profile Jens KIILGAARD | Professor Senior Consultant | PhD, MD, FEBO | Rigshospitalet, Copenhagen | rigshospitalet | Department of Ophthalmology | Research profile](https://i1.rgstatic.net/ii/profile.image/11431281087388208-1664571618570_Q512/Jens-Kiilgaard.jpg)
Jens KIILGAARD | Professor Senior Consultant | PhD, MD, FEBO | Rigshospitalet, Copenhagen | rigshospitalet | Department of Ophthalmology | Research profile
![J&J's Remicade sees 'very little' biosim erosion, but payers are sticking it to Xarelto | Fierce Pharma J&J's Remicade sees 'very little' biosim erosion, but payers are sticking it to Xarelto | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/2017-02/jnjpublicdomain.jpg?VersionId=YSlyh1jWhCCxgm16CxjeuowwmLER3FyB)